scholarly journals The effect of vitamin K1 on VEGF levels in chick embryos with type 1 diabetes and Diabetic Retinopathy induced by streptozotocin

2021 ◽  
Vol 8 (9) ◽  
pp. 551-555
Author(s):  
Erhan Bozkurt ◽  
Emre Atay ◽  
Oğuz Han Koca ◽  
Mehmet Cem Sabaner
Keyword(s):  
Diabetic Retinopathy ◽  
Blood Glucose ◽  
Growth Factor ◽  
Early Stage ◽  
Vitamin K1 ◽  
Chick Embryos ◽  
Blood Insulin ◽  
Glucose Levels ◽  
Specific Pathogen ◽  
Endothelial Growth Factor

Objective: Hyperglycemia caused by Diabetes Mellitus (DM) is associated with long-term dysfunction such as diabetic retinopathy (DRP). The most effective growth factor in the development of DRP is the vascular endothelial growth factor (VEGF). Vitamin K1 reduces hyperglycemia and prevents the development of DM. In this study, we aimed to create streptozotocin (STZ) induced DM and DRP in chick embryos and to show whether vitamin K1 can prevent early-stage DRP by measuring VEGF levels. Material and Methods: The 140 specific pathogen-free (SPF) fertilized chicken eggs were used in this study. Three different STZ doses were administered to 120 SPF eggs for an induced DM model. Three different vitamin K1 doses were administered in each STZ dose group. On the 12th day and 18th day the remaining 20 SPF eggs were separated as control groups. On the 18th-day, blood glucose, blood insulin and VEGF levels were measured. Results: 0.45 mg/egg STZ dose (STZ3) was determined as the optimal/ideal dose for the DM model. When the group-administered STZ3 and vitamin K1 were evaluated among themselves; it was determined that there were significant changes in blood glucose, blood insulin, VEGF levels of the STZ3+K1-3 group compared to the STZ3+K1-1 and STZ3+K1-2 groups (p<0.05). Conclusion: Vitamin K1 increases blood insulin levels and decreases blood glucose levels. When hyperglycemia reduces, the VEGF levels reduce. Vitamin K1 protects from DRP by reducing VEGF levels.

scholarly journals Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy

2020 ◽  
Vol 21 (17) ◽  
pp. 6243 ◽  
Author(s):  
Yohei Tomita ◽  
Deokho Lee ◽  
Yukihiro Miwa ◽  
Xiaoyan Jiang ◽  
Masayuki Ohta ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Blood Glucose ◽  
Vision Loss ◽  
Early Stage ◽  
Neural Function ◽  
Peroxisome Proliferator ◽  
Diabetic Mice ◽  
Peroxisome Proliferator Activated Receptor ◽  
Glucose Levels ◽  
Adult Mice

Diabetic retinopathy (DR) is one of the leading causes of blindness globally. Retinal neuronal abnormalities occur in the early stage in DR. Therefore, maintaining retinal neuronal activity in DR may prevent vision loss. Previously, pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, was suggested as a promising drug in hypertriglyceridemia. However, the role of pemafibrate remains obscure in DR. Therefore, we aimed to unravel systemic and retinal changes by pemafibrate in diabetes. Adult mice were intraperitoneally injected with streptozotocin (STZ) to induce diabetes. After STZ injection, diet supplemented with pemafibrate was given to STZ-induced diabetic mice for 12 weeks. During the experiment period, body weight and blood glucose levels were examined. Electroretinography was performed to check the retinal neural function. After sacrifice, the retina, liver, and blood samples were subjected to molecular analyses. We found pemafibrate mildly improved blood glucose level as well as lipid metabolism, boosted liver function, increased serum fibroblast growth factor21 level, restored retinal functional deficits, and increased retinal synaptophysin protein expression in STZ-induced diabetic mice. Our present data suggest a promising pemafibrate therapy for the prevention of early DR by improving systemic metabolism and protecting retinal function.

scholarly journals Relationship between Serum Vascular Endothelial Growth Factor Levels and Stages of Diabetic Retinopathy and Other Biomarkers

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Nakhleh E. Abu-Yaghi ◽  
Nafez M. Abu Tarboush ◽  
Ala M. Abojaradeh ◽  
Amal S. Al-Akily ◽  
Esra’a M. Abdo ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Glycosylated Hemoglobin ◽  
Density Lipoprotein ◽  
Significant Negative Correlation ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Dm Type 2

Aim. This study aims to measure serum vascular endothelial growth factor (VEGF) levels in a sample of Jordanian patients and to determine their relationship with the different stages of diabetic retinopathy. It also explores the correlation between VEGF concentrations and different biochemical and demographic findings. Materials and Methods. A total of 167 adults participated in the study. Participants were divided into two main categories: patients with diabetes mellitus (DM) type 2 without diabetic retinopathy (DR) (N = 62) and patients with DM type 2 affected by DR (N = 105). DR patients were further subclassified into nonproliferative (N = 41) and proliferative (N = 64). Basic laboratory tests were measured to correlate with VEGF levels. Irisin, a hormone linked to diabetic retinopathy was also measured and correlated with VEGF. Results. Serum VEGF was found to positively correlate with the severity of diabetic retinopathy. The means of VEGF serum concentrations were 60 pg/mL for controls, 133 pg/mL for nonproliferative DR patients, and 229 pg/mL for proliferative DR patients. We found a significant positive correlation with glycosylated hemoglobin (HbA1c), and a significant negative correlation with high-density lipoprotein (HDL) levels, age, and irisin. Conclusion. In this cohort of Jordanian diabetics, serum VEGF concentrations strongly correlated with the presence and stages of diabetic retinopathy, suggesting it as an appropriate indicator for diabetic retinopathy early detection and management in this society. VEGF levels also significantly correlated with HbA1c, HDL, and irisin levels. Further studies are encouraged to explore these relationships in other ethnic groups and with different diabetic complications.

scholarly journals Effects of refraction and axial length on the development and progression of diabetic retinopathy

2021 ◽  
Vol 21 (4) ◽  
pp. 205-209
Author(s):  
M.M. Bikbov ◽  
◽  
O.I. Orenburkina ◽  
A.E. Babushkin ◽  
A.A. Fakhretdinova ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Axial Length ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Vascular Endothelial ◽  
Keywords Diabetic Retinopathy ◽  
Eye Disorders ◽  
Endothelial Growth Factor

Eye disorders have a special place in diabetes since visual impairment has a significant effect on the quality of life. Therefore, determining risk factors and prognostic criteria for disease course are essential for developing strategies for early prevention of diabetic retinopathy (DR). This paper addresses studies on various aspects of DR in patients with myopia. It was demonstrated that DR arises, develops, and progresses in different ways under various axial lengths (AL). Thus, many authors report that DR barely occurs in high myopia. Some of them account for this phenomenon for poor blood circulation in a long myopic eye. Others refer to a significantly lower vascular endothelial growth factor (VEGF) concentration in longer eyes or eyes with myopic refraction. The third authors argue a focal disintegration of retinal pigment epithelium to eliminate metabolic end products through the choroid and sclera. As a result, neither acidosis nor venous congestion develops, and endothelial barrier function remains unaffected Keywords: diabetic retinopathy, myopia, axial length, vascular endothelial growth factor, emmetropia, hyperopia, diabetes. For citation: Bikbov M.M., Orenburkina O.I., Babushkin A.E., Fakhretdinova A.A. Effects of refraction and axial length on the development and progression of diabetic retinopathy. Russian Journal of Clinical Ophthalmology. 2021;21(4):205–209 (in Russ.). DOI: 10.32364/2311-7729- 2021-21-4-205-209.

Sign in / Sign up

Export Citation Format

Share Document